PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSparsentan
Sparsentan
Filspari (sparsentan) is a small molecule pharmaceutical. Sparsentan was first approved as Filspari on 2023-02-17. It is used to treat proteinuria in the USA. The pharmaceutical is active against type-1 angiotensin II receptor and endothelin-1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Filspari
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sparsentan
Tradename
Company
Number
Date
Products
FILSPARITravere TherapeuticsN-216403 RX2023-02-17
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
daranjoOTC monograph not final2020-09-07
daraprimNew Drug Application2023-12-07
darzalexBiologic Licensing Application2021-09-10
darzalex darzalex ivBiologic Licensing Application2025-04-15
darzalex fasproBiologic Licensing Application2024-08-08
filspariNew Drug Application2025-08-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
proteinuria—D011507R80
Agency Specific
FDA
EMA
Expiration
Code
SPARSENTAN, FILSPARI, TRAVERE
2030-02-17ODE-389
2028-02-17NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Sparsentan, Filspari, Travere
99934612030-03-29U-3269
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
90 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.01838101461
Plasma cell neoplasmsD054219——102351439
Iga glomerulonephritisD005922EFO_0004194——311—5
Focal segmental glomerulosclerosisD005923EFO_0004236——211—4
Kidney diseasesD007674EFO_0003086N08—2—1—3
Kidney transplantationD016030—————112
ProteinuriaD011507—R80———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immunoglobulin light-chain amyloidosisD000075363———11—35
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AmyloidosisD000686EFO_1001875E85—2——35
RecurrenceD012008——23——14
Smoldering multiple myelomaD000075122———3———3
LeukemiaD007938—C9522———3
ParaproteinemiasD010265—D47.2—3———3
HypertensionD006973EFO_0000537I10—2———2
LymphomaD008223—C85.921———2
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.021———2
Precursor t-cell lymphoblastic leukemia-lymphomaD054218——21———2
Lymphoid leukemiaD007945—C9121———2
Show 24 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Renal insufficiencyD051437—N191————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSparsentan
INNsparsentan
Description
Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist. It is taken by mouth.
Classification
Small molecule
Drug classendothelin receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
Identifiers
PDB—
CAS-ID254740-64-2
RxCUI—
ChEMBL IDCHEMBL539423
ChEBI ID—
PubChem CID10257882
DrugBankDB12548
UNII ID9242RO5URM (ChemIDplus, GSRS)
Target
Agency Approved
AGTR1
AGTR1
EDNRA
EDNRA
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
185
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Q8TBK4
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Darzalex – Johnson & Johnson
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Filspari – Travere Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Filspari – Ligand Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,019 documents
View more details
Safety
Black-box Warning
Black-box warning for: Filspari
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
72,504 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use